SUZANNE HANLE: Open Payments
NPI 1053836890 · LITTLETON, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$634 in 28 payments from 12 companies in 2025. Trend: 2023 $901 · 2024 $1,790 · 2025 $634
Food & beverage: $634
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $129 |
| ABBVIE INC. | 4 | $86 |
| Braeburn Inc. | 4 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $75 |
| Neurocrine BioSciences, Inc. | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Alkermes, Inc. | 2 | $30 |
Products named: COBENFY, VRAYLAR, BRIXADI, CAPLYTA, INGREZZA, REXULTI, TRINTELLIX, Auvelity.
Industry payments across CO — which companies pay providers there.
